Clinical Trials · NCT01381926
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
- Phase
- Phase 4
- Recruitment status
- Terminated
- Sponsor
- University of Alabama at Birmingham
- Enrollment
- 14
- Start date
- Feb 2011
- Locations
- 1 site, United States
- Primary endpoint
- Determine Changes in Bone Resorption Markers During the Treatment With a GLP-1 Receptor Agonist (Exenatide) Compared to Placebo in Patients With T2DM.